For citation:
Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Y.E. BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2015;8(1):39-46. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.1.039-046
Views: 69
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 